Gefitinib-Induced Severe Dermatological Adverse Reactions: A Case Report and Pharmacogenetic Profile

• المؤلفون الرئيسيون: Mariana Vieira Morau (مؤلف), Cecilia Souto Seguin (مؤلف), Mauricio Wesley Perroud Junior (مؤلف), Carolina Dagli-Hernandez (مؤلف), Eder de Carvalho Pincinato (مؤلف), Patricia Moriel (مؤلف)
• التنسيق: كتاب
• منشور في: MDPI AG, 2024-08-01T00:00:00Z.
• الموضوعات: article
• الوصول للمادة أونلاين: Connect to this object online.

Gefitinib is a selective inhibitor of the epidermal growth factor receptor that is used to treat advanced and metastatic non-small cell lung cancer (NSCLC). Dermatological adverse reactions are most commonly associated with gefitinib treatment. The cause of adverse reactions in individuals is multif...